| Title |
Arterial Thrombosis in Patients with Cancer
|
|---|---|
| Published in |
Current Treatment Options in Cardiovascular Medicine, April 2018
|
| DOI | 10.1007/s11936-018-0635-x |
| Pubmed ID | |
| Authors |
Mirela Tuzovic, Joerg Herrmann, Cezar Iliescu, Kostas Marmagkiolis, Boback Ziaeian, Eric H. Yang |
| Abstract |
Cancer is a common cause of morbidity and mortality in the USA. While the association between venous thrombosis and malignancy is well established, arterial thrombosis has more recently been recognized as a serious complication of cancer and certain chemotherapeutic agents. This review aims to summarize the most recent literature regarding the incidence and risk factors for cancer-related arterial thrombosis, understand the pathophysiologic mechanisms of thrombosis, and highlight the specific diagnostic and treatment considerations relevant to cancer patients. Based on a recent study looking at the Surveillance, Epidemiology, and End Results (SEER) database, the incidence of arterial thromboembolic events (ATEs) in patients with cancer at 6 months is 4.7%; the presence of an ATE is predictive of worse outcomes. Certain drugs such as platinum-based agents, vascular endothelial growth factor inhibitors, tyrosine kinase inhibitors, and taxanes have been associated with high rates of ATEs. Increased platelet reactivity appears crucial to development of arterial thrombosis in cancer patients. Cancer patients have an increased risk of arterial thrombosis that is likely due to both a cancer-associated procoagulant state as well as the adverse effects of certain chemotherapeutic agents. Treatment of arterial thromboembolism in cancer patients typically requires a multidisciplinary approach in part due to high rates of thrombocytopenia and stent thrombosis in the setting of percutaneous interventions. More studies are needed to investigate optimal prophylaxis, surveillance strategies, and treatments of cancer-related arterial thromboembolic disease. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 50% |
| Belgium | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 2 | 50% |
| Scientists | 1 | 25% |
| Members of the public | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 83 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 83 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 12 | 14% |
| Researcher | 11 | 13% |
| Student > Ph. D. Student | 7 | 8% |
| Other | 6 | 7% |
| Student > Master | 5 | 6% |
| Other | 10 | 12% |
| Unknown | 32 | 39% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 34% |
| Biochemistry, Genetics and Molecular Biology | 5 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Agricultural and Biological Sciences | 4 | 5% |
| Engineering | 2 | 2% |
| Other | 4 | 5% |
| Unknown | 36 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 February 2019.
All research outputs
#13,075,788
of 23,041,514 outputs
Outputs from Current Treatment Options in Cardiovascular Medicine
#231
of 416 outputs
Outputs of similar age
#159,379
of 328,950 outputs
Outputs of similar age from Current Treatment Options in Cardiovascular Medicine
#11
of 22 outputs
Altmetric has tracked 23,041,514 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 416 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 328,950 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.